MBX Biosciences (MBX) Corporate presentation summary

Strategic focus and mission

• Focused on developing precision peptide therapies for endocrine and metabolic diseases, aiming to transform patient lives through innovative drug design.

• Proprietary PEP platform enables multi-mechanism peptides, programmable prodrugs, and fatty acylation for optimized dosing and efficacy.

Financial position and milestones

• Holds $418.6 million in cash, projected to fund operations into 2029.

• Key 2026 milestones include Phase 3 initiation for canvuparatide, Phase 1 MAD results for MBX 4291 and MBX 5765, and development candidate nomination for MBX 6180.

Endocrine pipeline: Canvuparatide for hypoparathyroidism

• Canvuparatide is a once-weekly PTH replacement therapy in pivotal Phase 3 for chronic hypoparathyroidism.

• Phase 2 data show competitive responder rates versus daily injectable therapies, with potential to become new standard of care.

• Phase 3 trial includes a 26-week double-blind period and 78-week open-label extension, focusing on normalization of serum calcium and independence from supplements.